Cardiol Therapeutics Inc.
CRDL.TO
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -17.43% | 31.04% | 48.15% | 66.29% | 61.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.86% | 23.08% | 28.79% | 33.21% | 23.16% |
| Operating Income | 7.86% | -23.08% | -28.79% | -33.21% | -23.16% |
| Income Before Tax | 6.33% | -24.60% | -15.00% | -28.61% | -27.99% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 6.33% | -24.60% | -15.00% | -28.61% | -27.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.33% | -24.60% | -15.00% | -28.61% | -27.99% |
| EBIT | 7.86% | -23.08% | -28.79% | -33.21% | -23.16% |
| EBITDA | 7.19% | -23.08% | -28.64% | -32.90% | -22.87% |
| EPS Basic | 22.99% | -7.15% | -1.05% | -16.80% | -20.72% |
| Normalized Basic EPS | 23.00% | -7.17% | -1.07% | -16.89% | -20.81% |
| EPS Diluted | 22.99% | -7.15% | -1.05% | -16.80% | -20.72% |
| Normalized Diluted EPS | 23.00% | -7.17% | -1.07% | -16.89% | -20.81% |
| Average Basic Shares Outstanding | 21.91% | 18.76% | 15.55% | 11.02% | 5.65% |
| Average Diluted Shares Outstanding | 21.91% | 18.76% | 15.55% | 11.02% | 5.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |